Nexalin Technology, Inc. (NXL) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US65345B2016

Price
1.49 USD
Market cap
814,159.10 USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Nexalin Technology, Inc. financials

Fiscal year2025
Revenue301,647.00 USD
Gross profit240,274.00 USD
Operating income-8.39 m USD
EBIT-8.23 m USD
Net income-8.22 m USD
Diluted EPS – continuing operations-0.50 USD

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Nexalin Technology, Inc.

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.